Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells $89,922.95 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director now owns 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded down $0.31 during trading on Thursday, reaching $37.12. 586,991 shares of the company traded hands, compared to its average volume of 833,847. The stock's 50 day moving average price is $36.58 and its two-hundred day moving average price is $39.41. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -6.31 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The firm's revenue was up 28.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.03) earnings per share. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RARE shares. JPMorgan Chase & Co. boosted their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. William Blair started coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target on the stock. Guggenheim restated a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Piper Sandler lowered their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of RARE. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after acquiring an additional 965,919 shares in the last quarter. Norges Bank acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $40,463,000. Vestal Point Capital LP boosted its holdings in shares of Ultragenyx Pharmaceutical by 100.0% in the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock worth $63,105,000 after acquiring an additional 750,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Ultragenyx Pharmaceutical by 28.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after acquiring an additional 706,519 shares in the last quarter. Finally, Deep Track Capital LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $27,493,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.